Inarigivir soproxil is primarily investigated for its antiviral properties, particularly in the treatment of chronic hepatitis B virus (HBV) infection. It functions by modulating the host immune response, enhancing the body's ability to combat the virus. This compound has shown potential in reducing viral load and improving liver function in clinical studies. Its unique mechanism of action, which involves activating innate immune pathways, sets it apart from traditional antiviral therapies. Research continues to explore its efficacy and safety as a promising therapeutic option for HBV patients.